| Literature DB >> 26227158 |
Michelle J Smith1, Beau R Webber1, Mahmood Mohtashami2, Heather E Stefanski1, Juan Carlos Zúñiga-Pflücker2, Bruce R Blazar1.
Abstract
T lymphocytes are critical mediators of the adaptive immune system and have the capacity to serve as therapeutic agents in the areas of transplant and cancer immunotherapy. While T cells can be isolated and expanded from patients, T cells derived in vitro from both hematopoietic stem/progenitor cells (HSPCs) and human pluripotent stem cells (hPSCs) offer great potential advantages in generating a self-renewing source of T cells that can be readily genetically modified. T-cell differentiation in vivo is a complex process requiring tightly regulated signals; providing the correct signals in vitro to induce T-cell lineage commitment followed by their development into mature, functional, single positive T cells, is similarly complex. In this review, we discuss current methods for the in vitro derivation of T cells from murine and human HSPCs and hPSCs that use feeder-cell and feeder-cell-free systems. Furthermore, we explore their potential for adoption for use in T-cell-based therapies.Entities:
Keywords: CD34 +; Cell culture; Cord blood; Differentiation; Embryonic stem cells; Hematopoietic stem cells; Induced pluripotent stem cells; T cells
Mesh:
Year: 2015 PMID: 26227158 PMCID: PMC4762024 DOI: 10.1002/stem.2115
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277